Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa; Says on Track to File NDA in Mid 2016

IRVINE , Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. AERI, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on September 23, dosing commenced of the first patients enrolled in Rocket 4, the Company's fourth Phase 3 clinical trial of RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Aerie anticipates total enrollment of approximately 700 patients in this two-arm 90-day efficacy study, comparing once-daily RhopressaTM for non-inferiority to twice daily timolol. The range for the primary endpoint mirrors Aerie's successful Rocket 2 trial, and includes patients with baseline IOPs ranging from above 20 mmHg (millimeters See full press release